Revival Health Inc. and Quanta Computer Inc. announced a strategic partnership to enable U.S. based manufacturing capabilities of millions of rapid tests for both COVID-19 (SARS-CoV-2) and blood biomarker tests. This partnership will leverage Revival's rapid testing platform LumiNow? and unique, end-to-end healthcare ecosystem?Move 78?, with Quanta's manufacturing and robotics operational expertise. Revival's rapid test platform, LumiNow?, enables easy-to-use, lab-free, 20-minute antigen testing for COVID-19 (SARS-CoV-2). Early testing indicates excellent sensitivity in the order of cycle-time (CT) 31 which could lead to the identification of asymptomatic persons. The LumiNow? digital lateral flow test (LFT) and innovative spectral sensor delivers a unique combination of sensitivity, at-home use, and low cost. LumiNow? delivers: High Accuracy and Sensitivity ? Innovative LFT combined with spectral sensing ?quantitative verification is done by C-reactive protein (CRP) testing to concentrations as low as tens of pg./ml, which is a factor of 10x more sensitive than standard rapid-test read-out devices. Easy-to-use ? No user interpretation ? results via Bluetooth to a smartphone app ? video app guidance. Secure ? LumiNow? platform processes data in a secure medical cloud ? IEC-62304 compliance, regulatory instances (CE, FDA, TGA, CFDA) and GDPR and HIPAA standards.